FIELD: medicine.
SUBSTANCE: invention refers to diagnostic techniques for hepatic fibrosis in an individual involving urokinase plasminogen, matrix metalloproteinase 9 and β-2-microglobulin expression tests to derive a score and to diagnose. Also, the present invention refers to a diagnostic kit for hepatic fibrosis comprising a first antibody specifically bound to an urokinase plasminogen activator (uPA), a second antibody specifically bound to matrix metalloproteinase 9 (MMP9) and a third antibody specifically bound to β-2-microglobulin (β-2-MG).
EFFECT: higher diagnostic accuracy.
17 cl, 33 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SCREENING PROBABILITY OF BLADDER CANCER | 2019 |
|
RU2718284C1 |
| GHRP-6-CONTAINING PHARMACEUTICAL COMPOSITION FOR PREVENTION AND REMOVAL OF FIBROSIS AND OTHER PATHOLOGICAL DEPOSITS IN TISSUES | 2007 |
|
RU2465913C2 |
| ANTIBODY ANALYSIS | 2017 |
|
RU2769987C2 |
| METHOD FOR DETERMINING THE PROBABILITY OF HEPATIC FIBROSIS IN PATIENTS PREVIOUSLY SUFFERING FROM COVID-19 | 2021 |
|
RU2764050C1 |
| USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
| VAP-1 INHIBITORS ADMINISTRATION FOR FIBROID DISEASES TREATMENT | 2010 |
|
RU2667963C1 |
| METHOD FOR PREDICTING RECOVERY OF SENSORIMOTOR FUNCTIONS IN PATIENTS WITH ACUTE ISCHEMIC STROKE AFTER EARLY REHABILITATION | 2021 |
|
RU2753140C1 |
| DIAGNOSTIC TECHNIQUE FOR MALIGNANT TUMOUR | 2010 |
|
RU2595854C2 |
| GPC3-TARGETED DRUG WHICH IS ADMINISTERED TO PATIENT SENSITIVE TO GPC3 DRUG-TARGETING THERAPY | 2013 |
|
RU2707882C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
